China Sky One Medical Prepares to Launch 13 New Products

HARBIN, China, March 22 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

    Since earlier SFDA approvals of these products, the Company has been
testing production quality and evaluating stability of the final manufacturing
process in preparation for commercial production. Commercialization
preparation for these 13 products is now complete or nearly complete and the
Company anticipates launching the products based on the following marketing
timetable.



    No.    Product Name          Description                   Expected
                                                               Marketing
                                                                 Time
    1      Oxymetazoline      To treat acute and chronic      March 2010
           Hydrochloride      rhinitis, sinusitis and
           Nasal Drops        allergic rhinitis

    2      Moschus Liniment   To relieve the pain from        March 2010
           for pain relief    scathe, wound, rheumatism and
                              arthrosis

    3      Ftibamzone         To treat herpes and fungal      April 2010
           Liniment           skin infection.

    4      Tobramycin Eye     To treat acute infection on     April 2010
           Drops              eyelids

    5      Calcium Folinate   An auxiliary therapy for sprue  May 2010
           Injection          (a disease of the small
                              intestine), malnutrition,
                              pregnancy- or infancy-related
                              megaloblastic anemia, and
                              colonic and rectal cancer

    6      Sodium             To treat allergic               May 2010
           Cromoglicate Eye   conjunctivitis
           Drops

    7      Aciclovir Gel      To treat the skin infection     June 2010
                              due to varicella-zoster virus
                              and the herpes simplex virus

    8      Antiasthma cream   To treat cough, asthma and      June 2010
                              chronic bronchitis

    9      Naphazoline        For the sterilization and       June 2010
           Hydrochloride      rheum prevention and for the
           Chlorpheniramine   treatment of rheumatic
           Maleate and        diseases
           Benzalkonium
           Bromide Spray

    10     Skincare Cream     To treat skin diseases such as  July 2010
                              acne, bottle nose,
                              chromophytosis and vitiligo

    11     Nasal Drop         To treat the sniffles           August 2010

    12     Propylgallate for  To treat cerebro-vascular       August 2010
           Injection          infarction, angina,
                              hypertention and coronary
                              heart diseases

    13     Dithranol          To treat different types of     September 2010
           ointment           psoriasis, such as plaque
                              psoriasis, guttate psoriasis
                              and hypertrophy psoriasis

"We look forward to the near-term launch of several products from our R&D pipeline and are now working on the sales forecast for these products diligently. Looking ahead, we are committed to provide more transparency to the investment community about the progress of our rich R&D pipeline. We expect to continue to diversify our rich product portfolio to strengthen the Company's competitive position and support sustainable long-term growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451- 87032617
     Email: [email protected]

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417
     Email: [email protected]
     Web:   http://www.ccgirasia.com

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353
     Email: [email protected]

SOURCE China Sky One Medical, Inc.